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Summary
Objective: Recent epidemiological studies identifying an association between some classes of
gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia
prompted our analysis. Our objective was to retrospectively apply data mining algorithms (DMAs)
to the Food and Drug Administration (FDA) drug safety database to see if they might have
directed/redirected attention to the reported association of gastric acid suppressive drugs with
C. difficile colitis and community-acquired pneumonia, prior to the published epidemiological
findings that supported the association.
Design: Two statistical DMAs, proportional reporting ratios (PRRs) and multi-item gamma Poisson
shrinker (MGPS), were applied to a spontaneous reporting system (SRS) database to identify
signals of disproportionate reporting (SDRs).
Results: SDRs related to community-acquired pneumonia were observed for two proton pump
inhibitors (lansoprazole and omeprazole), two H2 antagonists (famotidine and roxatidine), and
one antacid (magnesium silicate hydroxide). For C. difficile colitis, an SDR was generated for one
proton pump inhibitor (lansoprazole).
Conclusions: Although our analysis suggests that there may be an association between the SDRs
using SRS data and the epidemiological findings, these results may not have alerted public health
professionals in advance of published studies to an association between proton pump inhibitors/* Corresponding author. Tel.: +1 212 733 6143; fax: +1 212 808 8679.
E-mail address: Lester.Reich@pfizer.com (L. Reich).
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gastric acid suppressants and C. difficile colitis or community-acquired pneumonia. However, the
analysis reveals the potential utility of DMAs to direct attention to more subtle indirect drug adverse
effects in SRS databases that as yet are often identified from epidemiological investigations.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Clostridium difficile represents one of the most common
nosocomial infections in industrialized countries.1 The infec-
tion is primarily acquired following antibiotic therapy and is
the most frequent cause of colitis and infectious diarrhea in
hospitalized patients.2 An increased risk of C. difficile colitis
in hospitalized patients associated with the use of proton
pump inhibitors (PPIs) has been reported in recent analytic
studies conducted in one hospital in Montreal Quebec (cohort
and case—control)1 and a consortium of hospitals in Plymouth
UK (case—control).3 In addition, five epidemiological inves-
tigations (case—control, nested case—control, prospective
cohort, cross-sectional) have reported an increased risk of
community-acquired/nosocomial pneumonia and commu-
nity-acquired C. difficile disease in patients receiving PPIs
and/or H2 receptor antagonists.
4—8 Two other epidemiologi-
cal studies either did not find H2 receptor antagonists and
PPIs as risk factors for community-acquired pneumonia9 or
did not find an association between PPIs and nosocomial
pneumonia when compared to H2 receptor antagonists in
patients in a trauma unit.10 These nine studies were pub-
lished in the years 2003—2005.
To physicians involved in the practice of pharmacovigi-
lance, these studies and discussions surrounding the incon-
sistent results11—15 are of great interest. Although the trend
of the studies was toward the supporting of an association
between infection and gastric acid suppressants, different
studies addressing the same general issue gave conflicting
results; this will come as no surprise to those involved in
pharmacoepidemiology.
Pharmacovigilance is the science and activities relating to
the detection, assessment, understanding, and prevention of
adverse effects or any other drug-related problems.16 A
principal objective of pharmacovigilance is the timely detec-
tion of adverse events that are novel in relation to their
clinical nature, severity, and/or frequency as soon as possible
after approved clinical use commences, and with minimum
patient exposure.
After drug approval, pharmacovigilance is largely contin-
gent on submission of astute anecdotal clinical observations
to the medical literature and governmental health agencies/
pharmaceutical companies, especially in the form of spon-
taneous adverse event reports as well as post-marketing
clinical or epidemiological studies. Anecdotal observations
are important data sources for signal detection and hypoth-
esis generation, while the conventional post-marketing clin-
ical trials and epidemiological studies are data sources for
refining an index of suspicion and possibly hypothesis testing
although there is considerable debate on the latter point.17
Considerable research is being carried out on computer-
assisted signal detection algorithms, known as data mining
algorithms (DMAs), that can search large spontaneous report-
ing system (SRS) databases for statistical dependenciesbetween drugs and events in excess of what would be
expected if the drug and event were independently distrib-
uted in the database.18 If DMAs can detect ‘correlations’
between observed statistical dependencies and potential
drug—event relationships, they could significantly improve
our ability to detect signals of novel adverse events in the
post-approval period. Ideally, DMAs would be able to detect
associations between a drug and an adverse event in advance
of any published observational epidemiologic drug studies, at
which point, presumably far more individuals would have
been exposed to the drug in question.
There are two basic types of DMAs: (1) simple dispropor-
tionality analysis such as proportional reporting ratios
(PRRs)19 and reporting odds ratios (RORs)20 and (2) methods
that use additional statistical adjustments and Bayesian
modeling such as the multi-item gamma Poisson shrinker
(MGPS)21 and the Bayesian confidence propagation neural
network (BCPNN).22 The Bayesian methods were developed
to improve specificity by reducing potential ‘false positives.’
However, this increased specificity could potentially result in
credible signals beingmissed either absolutely or relatively in
terms of timing, at least with the common implementations
of the methods.23 These methods compare unexpected fre-
quencies of reports in the data set to the general pattern of
reporting frequencies. The observed number of reports of
particular drug event combinations (DECs) is compared to an
estimate of the expected number based on the broader
pattern of other reporting in the same data set as reflected
in an independence model. When a high number of cases are
observed relative to the ‘expected’ in an appropriate clinical
context then such DECs may be flagged for further investiga-
tion.22 Hence, these data mining methodologies are also
called disproportionality analyses. We are investigating the
potential utility and role of two DMAs — PRRs and MGPS — and
their role as adjuncts to our current pharmacovigilance
practices. In a previous publication24 in an infectious disease
epidemiology journal, we introduced a potential application
of DMAs using as an example an outbreak of endotoxin-like
reactions to intravenous gentamicin.
Findings from the quantitative methods (i.e., DMAs) in
pharmacovigilance have rarely been compared to findings
from epidemiological research.25,26 We considered the asso-
ciation between gastric acid suppressants and C. difficile
colitis/community-acquired pneumonia as particularly attrac-
tive for data mining research because the observed adverse
effects are postulated to be mediated by an intermediary
factor, which may be the type of events less likely to attract
the early attention of safety reviewers using traditional phar-
macovigilance practices. Our primary objective was tomake a
retrospective assessment of whether these evolving technol-
ogies (i.e., DMAs) in signal detection could have improved
pharmacovigilance practice by usefully directing/redirecting
attention to the association of proton pump inhibitors with
C. difficile colitis and community-acquired pneumonia prior to
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appearing in the literature in 2003—2004. A secondary objec-
tive was to give the reader some insight into these evolving
technologies and to provide suitable references for those
interested in learning more about DMAs.
Methods
Data source
The US Food and Drug Administration (FDA) drug safety
database adverse event reporting system (AERS) is a compu-
terized information database for post-approval safety sur-
veillance. It functions as an early warning system for adverse
drug events (ADEs) not detected during pre-approval testing.
It contains ADE reports with approved drugs and therapeutic
biological products submitted in accordance with mandatory
reporting obligations by pharmaceutical companies and
voluntarily by healthcare professionals and consumers.27
Adverse events are submitted on MedWatch forms. Adverse
event reports are reviewed and coded for data entry in
accordance with the standardized terminology of theMedical
Dictionary for Medical Regulatory Activities (MedDRA).
Quarterly extracts are available through the National Tech-
nical Information Service (NTIS). These quarterly updates are
subjected to extensive cleaning (i.e., removal of redundant
drug nomenclature and duplicate reports) prior to data
mining.
Data mining algorithms and thresholds
We retrospectively applied two DMAs (PRRs and MGPS: Lincoln
Technologies,Waltham,MA,USA) to theFDAAERSdatabase for
the period 1968 through the third quarter of 2003, usingTable 1 Findings from two datamining algorithms (PRR andMGPS)
Clostridium difficile colitis
Drugs Number of relevan
in the FDA AERS da
Antacids:
Aluminum compounds 0
Calcium compounds 0
Magnesium compounds 0
H2 antagonists:
Lafutidine 0
Cimetidine 10
Famotidine 10
Nizatidine 1
Ranitidine 16
Roxatidine 0
Proton pump inhibitors:
Esomeprazole 2
Omeprazole 34
Pantoprazole 4
Rabeprazole 3
Lansoprazole 29
PRR, proportional reporting ratios; MGPS, multi-item gamma Poisson s
reporting system; SDR, signal of disproportionate reporting.commonly cited disproportionality thresholds. For PRRs, the
commonly cited threshold, PRR > 2 with an associated x2 > 4
(with Yates correction), and N > 2,19 and for MGPS, EB05 > 2
and N > 021 were considered signals of disproportionate
reporting (SDRs). We used the term SDR to remove semantic
ambiguity that surrounds the term ‘signal’ alone and to
emphasize that DMAs don’t merely highlight potential
reported relationships that may or may not reflect causality
but may help generate hypotheses for further investigation,
depending on the clinical context inwhich they occur. TheEB05
is the lower 5th percentile of the 5-parameter posterior
gamma mixture around the empirical Bayes geometric mean
(EBGM),which is the geometricmean of the posterior distribu-
tion. These metrics may be regarded as variants of reporting
ratios or pseudo observed/expected (O/E) ratios. The DMAs
were applied to gastric acid suppressive/normalizing drugs in
the FDA AERS database to determine whether theymight have
directed the attention of safety reviewers to the association of
PPIs with C. difficile colitis and community-acquired pneumo-
nia prior to 2003, the year of publication of the first case—
control study and a retrospective survey.3,8
As mentioned earlier, adverse event data are encoded in
AERS using preferred terms (PTs) in the MedDRA, a highly
granular adverse event thesaurus.27 For this analysis, eight
possible C. difficile-related PTs (clostridial infection, clos-
tridium colitis, diarrhea hemorrhagic, diarrhea infectious,
gastroenteritis clostridial, necrotizing colitis, enterocolitis,
enterocolitis hemorrhagic) and 14 possible community-
acquired pneumonia-related PTs (bronchopneumonia, lobar
pneumonia, pneumonia, pneumonia bacterial, pneumonia
chlamydial, pneumonia haemophilus, pneumonia klebsiella,
pneumonia legionella, pneumonia mycoplasmal, pneumonia
pneumococcal, pneumonia primary atypical, pneumonia
salmonella, pneumonia staphylococcal, pneumonia strepto-using a drug safety database: gastric acid suppressant drugs and
t reports
tabase
SDR for C. difficile
(year of SDR)
—
—
—
—
No SDR
No SDR
No SDR
No SDR
—
No SDR
No SDR
No SDR
No SDR
SDR with PRR (2001—2003) and
MGPS (2002, 2003)
hrinker; FDA, Food and Drug Administration; AERS, adverse event
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Table 2 Findings from two datamining algorithms (PRR andMGPS) using a drug safety database: gastric acid suppressant drugs and
community-acquired pneumonia
Drugs Number of relevant reports
in the FDA AERS database
SDR for pneumonia (year of SDR) *
Antacids:
Algeldrate 1 No SDR
Calcium carbonate 2 No SDR
Magnesium oxide 3 No SDR
Magnesium silicate hydroxide 6 SDR with PRR (1997, 2003)
H2 antagonists:
Lafutidine 0 —
Cimetidine 108 No SDR
Nizatidine 23 No SDR
Ranitidine 98 No SDR
Famotidine 95 SDR with PRR (1989—1994)
Roxatidine 6 SDR with PRR (2001—2003)
Proton pump inhibitors:
Esomeprazole 6 No SDR
Pantoprazole 4 No SDR
Rabeprazole 4 No SDR
Lansoprazole 45 SDR with PRR (2002, 2003)
Omeprazole 93 SDR with PRR (1990)
PRR, proportional reporting ratios; MGPS, multi-item gamma Poisson shrinker; FDA, Food and Drug Administration; AERS, adverse event
reporting system; SDR, signal of disproportionate reporting (*no SDRs with MGPS).coccal) were selected and applied to the unique (single
entity) gastric acid suppressive/normalizing drugs (anta-
cids, 40; PPIs, 5; H2 receptor antagonists, 6) in AERS. Drug
event combinations and case counts were cumulatively
subsetted by year (i.e., the analysis by year included that
year, as well as previous years) to obtain the largest sample
size. For MGPS only, DECs were stratified by age, gender, and
year of report. Stratification is claimed to reduce ‘false
positives’ due to confounding but was not available for PRRs
in the program we used for the analysis. However, this claim
is based on the assumption of confounding versus effect
modification for all adverse events and this has not been
systematically confirmed.
Results
Tables 1 and 2 display the gastric acid suppressant drugs
(antacids, H2 receptor antagonists and PPIs), and the number
of relevant reports and SDRs with PRRs and/or MGPS for C.
difficile colitis and community-acquired pneumonia, respec-
tively. For C. difficile-related events, only one of nine gastric
acid suppressants provided an SDR (Table 1), whereas for
pneumonia-related events, five of 14 drugs for which there
were cases showed an SDR (Table 2).
SDRs persisting for more than a one-year period with the
more ‘sensitive’ PRR metric, were observed with one PPI
(lansoprazole) for a C. difficile-related event (Table 1) and
with one PPI (lansoprazole), one antacid (magnesium silicate
hydroxide), and two H2 antagonists (roxatidine, famotidine)
for a pneumonia-related event (Table 2). There was only one
persistent SDR with the more specific metric, EB05 > 2,
lansoprazole—enterocolitis hemorrhagic: EB05 = 5.7 (2002)
and 6.9 (2003). There were no obvious trends over time in
terms of the magnitude of the SDRs.Discussion
There are twomain activities where DMAs may be helpful: (1)
initial detection of signals/hypothesis generation and (2)
refining an index of suspicion associated with a signal
obtained by traditional or conventional methods. Although
our analysis suggests an association between the SDRs and the
epidemiological findings, these results in our opinion may not
have alerted public health professionals in advance of pub-
lished studies to an association between PPIs/gastric acid
suppressants and C. difficile colitis or community-acquired
pneumonia because they were not compelling in the sense of
being ‘patchy’ in the distribution across drugs. However, they
demonstrate a potential application for data mining not
previously specifically examined and reported in the litera-
ture: to help identify signals for spontaneously reported
adverse events possibly resulting from indirect effects of
drugs. By indirect effect we mean an adverse drug reaction
in which the causal pathway between drug and event is
mediated by an intervening pharmacodynamic effect. The
adverse effects of C. difficile colitis and community-acquired
pneumonia are postulated to bemediated by an intermediate
factor (reduced gastric acidity leading to bacterial over-
growth in the large intestine and oral cavity). In these types
of cases, the cause and effect relationship is indirect and not
readily evident to the clinician. Only small numbers of
reports could be expected, and thus ‘signals’ based on
reporting frequencies, a traditional pharmacovigilance tool,
might not be observed.
In this analysis, SDRs were generated for all three classes
of gastric acid suppressants, but only in a few of the drugs
studied. Given the proposed mechanism, if there was a true
association, one might expect SDRs for more gastric acid
suppressants, and especially with PPIs because these agents
Gastric acid suppressants, C. difficile colitis and community-acquired pneumonia 421are considered to be more effective when compared to
antacids and H2 receptor antagonists.
1 The lack of more SDRs
could indicate a ‘true negative’ or the absence of a causal
association. Indeed, this is discussed and alluded to in dis-
cussions surrounding published epidemiological studies.10—15
On the other hand, although there were only a relatively
small number of SDRs, when there was an SDR, the absolute
values for the individual SDRs were persistently high. It
should be kept in mind that SRSs are highly susceptible to
numerous reporting artifacts that lead to differential report-
ing, complicating such interpretations.
Although not an objective of our study, we were curious
whether the published studies had any effect on the genera-
tion of SDRs after the third quarter of 2003, the data endpoint
for our analysis. One of the myriad of factors that can bias
reporting to SRSs is publications.28 We therefore, post hoc,
extended our analysis to the second quarter of 2005, themost
recent data available. New persistent SDRs with PRRs (2004
through the second quarter 2005) were identified for ome-
prazole—pneumonia pneumococcal and ranitidine—clostri-
dial infection with a cumulative total of three and four
cases, respectively for each of the DECs. Thus, the published
literature did not substantially affect reporting and data
mining analysis after the third quarter of 2003.
Although disproportionality analysis should be robust to
‘non differential’ reporting artifacts, inherent limitations
associated with the passive surveillance of AERS, such as
under-reporting of non-serious adverse events, duplicate
reporting, higher reporting of adverse events in the first
few years of marketing and numerous other reporting arti-
facts, preclude making causal conclusions between drugs and
events based on this analysis. Further, the findings from this
nonsystematic analysis cannot be used to draw inferences
about the global performance characteristics of these tech-
niques. Determining the systematic performance character-
istics of DMAs requires testing multiple thresholds using each
algorithm in a diverse pharmacovigilance scenario.25 Since
these thresholds are somewhat arbitrary and adjustable, the
performance differential between PRRs and MGPS observed
in this exercise may not reflect performance differentials in
real-life pharmacovigilance settings. In addition, we did not
report on specificity, which would have allowed us to draw
some conclusions as to whether our analysis achieved dis-
criminant SDR generation with the gastric acid suppressants.
In this paper using one example, we explored the poten-
tial utility of data mining approaches for identifying indirect
effects of drugs, which may result in further investigation of
potential associations. Despite finding SDRs for the studied
DECs, it is unclear whether these results would have identi-
fied the drug—event relationships in advance of published
epidemiologic studies because of their lack of consistency.
Although there were some SDRs, almost all of which were
with the more sensitive/less specific metric PRRs, one might
have expected more SDRs with PPIs presumably because
these agents are considered to be more effective when
compared to antacids and H2 receptor antagonists. We com-
mend the investigators and health professionals who dili-
gently report clinical observations and epidemiological
studies on the safety ofmedicines to the published literature,
health authorities, and pharmaceutical companies. Although
the optimal uses of DMAs are the subject of research and
debate, they depend on the crucial data submitted byreporters to SRS databases that enhance the interface
between clinical observations and public health.
Conflict of interest: The authors are employees of phar-
maceutical companies, which manufacture and market drugs
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